Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 96Carcinoma, Non-Small-Cell Lung 85Prostatic Neoplasms 75Multiple Myeloma 74Neoplasms 50Leukemia, Myeloid, Acute 44Lymphoma 43Melanoma 42Neoplasm Metastasis 39Ovarian Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Lymphoma, Non-Hodgkin 34Lung Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 32Hematologic Neoplasms 29Colorectal Neoplasms 29Triple Negative Breast Neoplasms 27Hodgkin Disease 24Pancreatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 21Fallopian Tube Neoplasms 21Carcinoma, Renal Cell 21Sarcoma 20Lymphoma, Follicular 20Urinary Bladder Neoplasms 18Recurrence 18Lymphoma, Mantle-Cell 18Head and Neck Neoplasms 18Brain Neoplasms 18

Interventions

Gemtuzumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Acute × 90 days × Clear all
NCT00658814 2026-05-29

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
133 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡